How Do Kesimpta and Gilenya Work?
Kesimpta (ofatumumab) is a CD20-directed cytolytic monoclonal antibody given monthly by subcutaneous injection. It targets B cells to reduce inflammation in multiple sclerosis (MS). Gilenya (fingolimod) is an oral sphingosine 1-phosphate receptor modulator taken daily. It traps lymphocytes in lymph nodes, preventing them from entering the central nervous system and causing MS attacks.[1][2]
What Do Clinical Trials Show for Relapse Rates?
In the ASCLEPIOS trials, Kesimpta reduced annualized relapse rates by 50-59% compared to Aubagio (teriflunomide) in relapsing MS patients. Gilenya, in the FREEDOMS trial, cut relapse rates by 48-54% versus placebo. Head-to-head data is limited, but network meta-analyses rank Kesimpta slightly higher for relapse reduction in active relapsing-remitting MS (RRMS), especially in patients with high disease activity.[3][4]
Effectiveness on MRI Lesions and Disability Progression
Both drugs limit new brain lesions effectively. Kesimpta showed 82% fewer Gd-enhancing lesions than Aubagio; Gilenya reduced them by 82% versus placebo in trials. For disability, Kesimpta delayed 12-week confirmed disability progression (CDP) by 34% over Aubagio, while Gilenya slowed it by 24-30% versus placebo. Kesimpta may edge out in NEDA-3 (no evidence of disease activity) metrics in indirect comparisons.[3][5]
Side Effects and Safety Profile
Kesimpta carries risks of infections (upper respiratory tract common), injection reactions, and rare progressive multifocal leukoencephalopathy (PML). It lowers IgG levels over time. Gilenya has higher risks including bradycardia, macular edema, increased infections (herpes zoster), and PML (about 0.07 cases per 1,000 patient-years). Gilenya requires first-dose cardiac monitoring and ophthalmologic exams; Kesimpta does not. Liver enzyme elevations occur with both.[1][2][6]
| Aspect | Kesimpta | Gilenya |
|--------|----------|---------|
| Common side effects | Injection site reactions (20%), infections (50%) | Headache (25%), back pain (12%), hypertension (8%) |
| Serious risks | Hepatitis B reactivation, low immunoglobulins | Heart rhythm issues, skin cancer risk, pulmonary issues |
| Monitoring | Liver function, infections | Cardiac, eyes, skin, lungs, varicella status |
Who Gets Which Drug?
Kesimpta suits patients needing strong B-cell depletion with less frequent dosing, ideal for those avoiding daily pills or with cardiovascular risks. Gilenya fits oral therapy preference but not for patients with heart conditions, active infections, or basal cell carcinoma history. Neither is first-line; neurologists choose based on disease activity, comorbidities, and lifestyle.[7]
Cost and Access Comparison
Annual U.S. list price: Kesimpta ~$65,000-$70,000; Gilenya ~$60,000-$65,000 (generics available since 2022, dropping effective cost). Patient assistance programs exist for both. Gilenya patents expired (e.g., core composition in 2019), enabling generics; Kesimpta exclusivity runs through 2028-2032 depending on formulation.8
DrugPatentWatch.com tracks Gilenya's expired patents here: Gilenya Patents and Kesimpta's active ones: Kesimpta Patents.9
Can You Switch Between Them?
Switching is common in MS; from Gilenya to Kesimpta requires a 1-2 month washout due to lymphocyte sequestration. No direct superiority exists—choice depends on individual factors like relapse history and risk tolerance. Consult a neurologist for personalized assessment.
Sources
[1]: Kesimpta Prescribing Information - Novartis
[2]: Gilenya Prescribing Information - Novartis
[3]: Lancet Neurology (2020) - ASCLEPIOS I/II results
[4]: FREEDOMS Study - NEJM (2010)
[5]: Network meta-analysis, Neurology (2022)
[6]: FDA Labels
[7]: AAN Guidelines for MS DMTs (2021)
[8]: GoodRx pricing data (2024)